Leo Pharma to terminate up to 150 R&D jobs

10–15 percent of positions in Leo Pharma’s research and development unit will be trimmed as a consequence of the announced restructuring of the company. A new strategy is to motivate the remaining R&D team, says the company’s head of global research and development.
Leo Pharma is closing down around 10–15 percent of positions in its R&D unit | Photo: Leo Pharma/PR
Leo Pharma is closing down around 10–15 percent of positions in its R&D unit | Photo: Leo Pharma/PR
by ULRICH QUISTGAARD, translated by daniel pedersen

Dermatology firm Leo Pharma is closing between 100 and 150 jobs in its research and development unit, which currently counts around 1,000 employees.

Already a subscriber?Log in here

Read the whole article

Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

With your free trial you get:

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
!
!
Must contain at least 6 characters
!
Must contain at least 2 characters
!
Must contain at least 2 characters

Get full access for you and your coworkers

Start a free company trial today

Sign up for our newsletter

Stay ahead of development by receiving our newsletter on the latest sector knowledge.

!
Newsletter terms

Front page now

Further reading